Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials
Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that BIOS0635-048 tablets have received approval from...
Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that BIOS0635-048 tablets have received approval from...
Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) announced that its Category 2.2 modified drug Levetiracetam...
Bio-sincerity (SHE: 301096) announced that China’s National Medical Products Administration (NMPA) has approved its investigational...
Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced a strategic cooperation agreement with Delim Cosmetics...
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) and Xellar Biosystems announced a strategic cooperation agreement...
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) announced the signing of a cooperation agreement with...
Hangzhou Bio‑Sincerity Pharma‑Tech Corp., Ltd. (SHE: 301096) announced that its BIOS2242 oral solution has received...
Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology...
Hangzhou Bio‑Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS‑0625 tablet, a Class 1 small‑molecule...
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Hangzhou Bio‑Sincerity (SHE: 301096) today...
Hangzhou Bio-Sincerity Pharma-tech Corp., Ltd (SHE: 301096) has secured clinical trial approval from China’s National...